{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:05:53Z","timestamp":1779350753338,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2023.11.003","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T09:24:42Z","timestamp":1700213082000},"page":"S38-S43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Traditional and novel non-statin lipid-lowering drugs"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-4896","authenticated-orcid":false,"given":"Peeyush","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2023.11.003_bib1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2023.11.003_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 3","key":"10.1016\/j.ihj.2023.11.003_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003495-198800363-00009","article-title":"Helsinki Heart Study. New perspectives in the prevention of coronary heart disease","volume":"36","author":"Huttunen","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.ihj.2023.11.003_bib4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized Controlled Trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2023.11.003_bib5","first-page":"1563","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2012","journal-title":"N Engl J Med"},{"issue":"35\u201341","key":"10.1016\/j.ihj.2023.11.003_bib6","article-title":"Fibrates in combination with statins in the management of dyslipidemia","volume":"8","author":"Jacobson","year":"2006","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ihj.2023.11.003_bib7","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2174\/1389557521666210125144921","article-title":"Novel niacin receptor agonists: a promising Strategy for the treatment of dyslipidemia","volume":"21","author":"Kothawade","year":"2021","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ihj.2023.11.003_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1079\/BJN2002691","article-title":"UK Food Standards Agency alpha-linolenic acid workshop report","volume":"88","author":"Sanderson","year":"2002","journal-title":"Br J Nutr"},{"key":"10.1016\/j.ihj.2023.11.003_bib9","series-title":"Endotext [Internet]","article-title":"Triglyceride lowering drugs. 2021 Apr 1","author":"Feingold","year":"2000"},{"key":"10.1016\/j.ihj.2023.11.003_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentanoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomized open label blinded end point analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2023.11.003_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2023.11.003_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n 3 Fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2018","journal-title":"N Engl J Med"},{"issue":"73","key":"10.1016\/j.ihj.2023.11.003_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jpp\/rgab002","article-title":"Bile acid sequestrants: a review of mechanism and design","author":"Feng","year":"2021","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ihj.2023.11.003_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The lipid research clinics coronary primary prevention trial results I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2023.11.003_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/01.CIR.69.2.325","article-title":"The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary Intervention study","volume":"69","author":"Levy","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2023.11.003_bib16","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous artery bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2023.11.003_bib17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid \u2013lowering therapy in men with high levels of apoliopoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2023.11.003_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14728222.10.6.851","article-title":"Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview","volume":"10","author":"Gazi","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ihj.2023.11.003_bib19","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2023.11.003_bib20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2023.11.003_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/VHRM.S13496","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","author":"Hamilton-Craig","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ihj.2023.11.003_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Medicine"},{"key":"10.1016\/j.ihj.2023.11.003_bib23","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2023.11.003_bib24","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2023.11.003_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony open-label extension study)","volume":"174","author":"Ballantyne","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2023.11.003_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ihj.2023.11.003_bib27","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ihj.2023.11.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108369","article-title":"Effect of bempedoic acid on new onset or worsening diabetes: a meta-analysis","volume":"168","author":"Masson","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ihj.2023.11.003_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ihj.2023.11.003_bib30","first-page":"5594","article-title":"ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology solution set oversight committee","volume":"S0735\u20131097","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2023.11.003_bib31","first-page":"11","article-title":"Unmet need for further LDL-C lowering in India despite statin therapy: lipid association of India recommendations for the use of bempedoic acid","volume":"70","author":"Mehta","year":"2022","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.ihj.2023.11.003_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"A review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.ihj.2023.11.003_bib33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ihj.2023.11.003_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ihj.2023.11.003_bib35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"ORION-10 and ORION-11 investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2023.11.003_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.ihj.2023.11.003_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"A review of its clinical use, efficacy, and tolerability","volume":"14","author":"Lonso","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.ihj.2023.11.003_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.ihj.2023.11.003_bib39","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ihj.2023.11.003_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ihj.2023.11.003_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.ihj.2023.11.003_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein (a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"MEJM"},{"key":"10.1016\/j.ihj.2023.11.003_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11883-020-0826-2","article-title":"Nucleic acid\u2013based therapies for atherosclerosis","volume":"22","author":"M\u00e4kinen","year":"2020","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.ihj.2023.11.003_bib45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ihj.2023.11.003_bib46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14779072.2021.1955348","article-title":"Volanesorsen for treatment of familial chylomicronemia syndrome","volume":"19","author":"Lazarte","year":"2021","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223001761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223001761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:37:48Z","timestamp":1712626668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483223001761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"alternative-id":["S0019483223001761"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.003","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traditional and novel non-statin lipid-lowering drugs","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}